401 results on '"Babjuk, Marek"'
Search Results
2. Preoperative Plasma Insulin-Like Growth Factor-I and Its Binding Proteins-Based Risk Stratification of Patients Treated With Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
3. En bloc resection of bladder tumour: the rebirth of past through reminiscence
4. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non–muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study
5. Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma
6. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
7. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels
8. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
9. Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma
10. Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
11. Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study
12. Preoperative plasma insulin-like growth factor-I and its binding proteins-based risk stratification of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
13. MP51-04 PROGNOSTIC VALUE OF INSULIN-LIKE GROWTH FACTOR-I AND ITS BINDING PROTEINS-BASED IN PATIENTS TREATED WITH RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA
14. MP38-07 INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR AS BLOOD-BASED BIOMARKERS PREDICTING DISEASE OUTCOMES AFTER RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
15. MP38-06 PROGNOSTIC SIGNIFICANCE OF VCAM AND VEGF LEVELS PRIOR TO RADICAL NEPHROURETERECTOMY ON TREATMENT OUTCOMES
16. MP08-11 IMPACT OF PRE-SURGERY EGFR AND HER2 PLASMA LEVELS ON POST-SURGICAL OUTCOMES IN BLADDER CANCER PATIENTS RECEIVING RADICAL CYSTECTOMY
17. Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
18. Clinical and molecular response to alpha1‐oleate treatment in patients with bladder cancer.
19. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita
20. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review
21. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting
22. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees
23. Similar immune responses to alpha1‐oleate and Bacillus Calmette–Guérin treatment in patients with bladder cancer
24. En bloc resection for nonmuscle-invasive bladder cancer: selecting a proper laser
25. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex
26. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey
27. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
28. SIU–ICUD on bladder cancer: pathology
29. Comparison of MicroRNA Content in Plasma and Urine Indicates the Existence of a Transrenal Passage of Selected MicroRNAs
30. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review
31. Prognostic role of N-cadherin expression in patients with non–muscle-invasive bladder cancer
32. How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration
33. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
34. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
35. Long‐term prevention of bladder cancer progression by alpha1‐oleate alone or in combination with chemotherapy
36. How to follow the new EU Council recommendation and improve prostate cancer early detection:the Prostaforum 2022 declaration
37. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy
38. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration
39. Transurethral resection of bladder cancer with or without fluorescence
40. Candida sojae: First report of a human infection
41. What to do during Bacillus Calmette–Guérin shortage? Valid strategies based on evidence
42. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy
43. Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma
44. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer
45. PD14-08 COMPARATIVE OUTCOMES OF PRIMARY AND RECURRENT HIGH GRADE NON-MUSCLE INVASIVE AND PRIMARY AND PROGRESSIVE MUSCLE-INVASIVE BLADDER CANCER AFTER RADICAL CYSTECTOMY: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY
46. Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources
47. Hemicorporectomy – the ultimate solution of terminal pelvic sepsis
48. COMPLICATION RATES AFTER RADICAL CYSTECTOMY AFTER RADIOTHERAPY: AN INTERNATIONAL, MULTICENTER RETROSPECTIVE STUDY ON 609 CASES: PD12-12
49. Diagnostic and prognostic value of placental growth factor serum concentration in clear cell renal cell carcinoma
50. PD29-12 COMPARISON OF ONCOLOGICAL OUTCOMES OF DISTAL URETERAL ≤PT2 UROTHELIAL CARCINOMA MANAGED BY NEPHROURETERECTOMY, SEGMENTAL URETERECTOMY OR ENDOSCOPIC SURGERY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.